alzhemier's disease

  1. Biogen’s Alzheimer’s drug delayed; lack of clarity exists

    The analysts started scratching their heads during an earnings conference call as there was a lack of clarity in the delay in filing of Biogen's Alzheimer's drug. Last year, Biogen stock soared by 27% after the company optimistically said it would file an application with the US Food and Drug...
  2. Alzheimer’s disease trial - Axsome Therapeutics reports positive outcome

    Axsome Therapeutics stock skyrockets on positive outcome from Alzheimer's disease trial https://news.alphastreet.com/axsome-therapeutics-nasdaq-axsm-stock-almost-doubles-on-positive-outcome-from-alzheimers-disease-trial-in-premarket/
  3. Lilly partners with AC Immune

    Eli Lilly to collaborate with AC Immune for the treatment of Alzheimer’s disease. Will it succeed and create a drug to cure Alzheimer's disease?